{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T06:41:51Z","timestamp":1782369711844,"version":"3.54.5"},"reference-count":87,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2016,3,8]],"date-time":"2016-03-08T00:00:00Z","timestamp":1457395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"DOI":"10.1371\/journal.pmed.1001971","type":"journal-article","created":{"date-parts":[[2016,3,8]],"date-time":"2016-03-08T19:01:08Z","timestamp":1457463668000},"page":"e1001971","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":91,"title":["Cardiovascular and Renal Outcomes of Renin\u2013Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses"],"prefix":"10.1371","volume":"13","author":[{"given":"Ferr\u00e1n","family":"Catal\u00e1-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Mac\u00edas Saint-Gerons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Gonz\u00e1lez-Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe M.","family":"Rosano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry R.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Ridao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel","family":"Zaragoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Montero-Corominas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelio","family":"Tob\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar","family":"de la Fuente-Honrubia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Tabar\u00e9s-Seisdedos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,3,8]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0140-6736(15)60692-4","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries for 188 countries, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"386","year":"2015","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"Global, regional, and national age-sex specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1016\/S0140-6736(15)61340-X","article-title":"Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990\u20132013: quantifying the epidemiological transition","volume":"386","author":"CJ Murray","year":"2015","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"e1000236","DOI":"10.1371\/journal.pmed.1000236","article-title":"Event rates, hospital utilization, and costs associated with major complications of diabetes: a multicountry comparative analysis","volume":"7","author":"PM Clarke","year":"2010","journal-title":"PLoS Med"},{"key":"ref5","article-title":"Agency for Healthcare Research and Quality","author":"GD Sanders","year":"2011"},{"issue":"Suppl 1","key":"ref6","first-page":"S1","article-title":"Standards of medical care in diabetes\u20142015","volume":"38","year":"2015","journal-title":"Diabetes Care"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"PA James","year":"2014","journal-title":"JAMA"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","article-title":"ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD)","volume":"34","author":"L Ryd\u00e9n","year":"2013","journal-title":"Eur Heart J"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.cjca.2014.02.002","article-title":"The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension","volume":"30","author":"K Dasgupta","year":"2014","journal-title":"Can J Cardiol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/bmj.317.7160.713","article-title":"Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39","volume":"317","year":"1998","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2337\/diacare.21.4.597","article-title":"Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM","volume":"21","author":"P Tatti","year":"1998","journal-title":"Diabetes Care"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM199803053381003","article-title":"The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension","volume":"338","author":"RO Estacio","year":"1998","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1097\/00004872-200018110-00020","article-title":"Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2","volume":"18","author":"LH Lindholm","year":"2000","journal-title":"Study Group. J Hypertens"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.2337\/diacare.24.12.2091","article-title":"CAPPP Study Group. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic\/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project","volume":"24","author":"L Niskanen","year":"2001","journal-title":"Diabetes Care"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"EJ Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"HH Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"BM Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0140-6736(02)08090-X","article-title":"Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol","volume":"359","author":"LH Lindholm","year":"2002","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/archinte.165.12.1401","article-title":"Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"165","author":"PK Whelton","year":"2005","journal-title":"Arch Intern Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","author":"A Patel","year":"2007","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"HH Parving","year":"2012","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamainternmed.2014.348","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis","volume":"174","author":"J Cheng","year":"2014","journal-title":"JAMA Intern Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"f6008","DOI":"10.1136\/bmj.f6008","article-title":"Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and Bayesian network meta-analysis","volume":"347","author":"HY Wu","year":"2013","journal-title":"BMJ"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s00125-011-2398-8","article-title":"Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis","volume":"55","author":"P Vejakama","year":"2012","journal-title":"Diabetologia"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.diabres.2011.11.025","article-title":"Effects of renin-angiotensin system blockades on cardiovascular outcomes in patients with diabetes mellitus: a systematic review and meta-analysis","volume":"96","author":"YM Nakao","year":"2012","journal-title":"Diabetes Res Clin Pract"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(05)67814-2","article-title":"Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis","volume":"366","author":"JP Casas","year":"2005","journal-title":"Lancet"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/bmj.38237.585000.7C","article-title":"Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review","volume":"329","author":"GF Strippoli","year":"2004","journal-title":"BMJ"},{"key":"ref29","first-page":"CD008170","article-title":"First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension","volume":"1","author":"H Xue","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"f360","DOI":"10.1136\/bmj.f360","article-title":"Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomized trials","volume":"346","author":"H Makani","year":"2013","journal-title":"BMJ"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2012.10.011","article-title":"A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure","volume":"61","author":"G Savarese","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/eurheartj\/ehs075","article-title":"Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients","volume":"33","author":"LC van Vark","year":"2012","journal-title":"Eur Heart J"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/archinternmed.2010.427","article-title":"Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk","volume":"171","author":"S Sciarretta","year":"2011","journal-title":"Arch Intern Med"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"d2234","DOI":"10.1136\/bmj.d2234","article-title":"Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials","volume":"342","author":"S Bangalore","year":"2011","journal-title":"BMJ"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"e9946","DOI":"10.1371\/journal.pone.0009946","article-title":"Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure","volume":"5","author":"A Kuenzli","year":"2010","journal-title":"PLoS ONE"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"861","DOI":"10.7326\/0000605-200912150-00162","article-title":"Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease","volume":"151","author":"WL Baker","year":"2009","journal-title":"Ann Intern Med"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1001\/jama.289.19.2534","article-title":"Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis","volume":"289","author":"BM Psaty","year":"2003","journal-title":"JAMA"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"S Julius","year":"2004","journal-title":"Lancet"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"MA Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"S Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"JF Mann","year":"2008","journal-title":"Lancet"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(14)62459-4","article-title":"Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis","volume":"385","author":"SC Palmer","year":"2015","journal-title":"Lancet"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"D Moher","year":"2009","journal-title":"PLoS Med"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"B Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jclinepi.2007.10.003","article-title":"Surveillance search techniques identified the need to update systematic reviews","volume":"61","author":"M Sampson","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/2046-4053-2-44","article-title":"Comparative effectiveness of monotherapies and combination therapies for patients with hypertension: protocol for a systematic review with network meta-analyses","volume":"2","author":"B Hutton","year":"2013","journal-title":"Syst Rev"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1056\/NEJMoa0804593","article-title":"Telmisartan to prevent recurrent stroke and cardiovascular events","volume":"359","author":"S Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","article-title":"Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial","volume":"372","author":"S Yusuf","year":"2008","journal-title":"Lancet"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-151-1-200907070-00122","article-title":"Effect of telmisartan on renal outcomes: a randomized trial","volume":"151","author":"JF Mann","year":"2009","journal-title":"Ann Intern Med"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"H Haller","year":"2011","journal-title":"N Engl J Med"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1093\/eurheartj\/ehi225","article-title":"The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy","volume":"26","author":"CA Daly","year":"2005","journal-title":"Eur Heart J"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/S0140-6736(08)61412-9","article-title":"Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials","volume":"372","author":"N Chaturvedi","year":"2008","journal-title":"Lancet"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"11","DOI":"10.7326\/0003-4819-151-1-200907070-00120","article-title":"Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials","volume":"151","author":"R Bilous","year":"2009","journal-title":"Ann Intern Med"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(08)61411-7","article-title":"Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomized placebo-controlled trial","volume":"372","author":"AK Sj\u00f8lie","year":"2008","journal-title":"Lancet"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"JN Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/jama.2013.1954","article-title":"Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial","volume":"309","author":"M Gheorghiade","year":"2013","journal-title":"JAMA"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/hr.2010.38","article-title":"Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial","volume":"33","author":"K Nakao","year":"2010","journal-title":"Hypertens Res"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1097\/HJH.0000000000000281","article-title":"Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial","volume":"32","author":"T Ogihara","year":"2014","journal-title":"J Hypertens"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/hr.2014.23","article-title":"Sex differences in response to angiotensin II receptor blocker-based therapy in elderly, high-risk, hypertensive Japanese patients: a subanalysis of the OSCAR study","volume":"37","author":"K Matsui","year":"2014","journal-title":"Hypertens Res"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"JP Higgins","year":"2011","journal-title":"BMJ"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"H Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"MA Puhan","year":"2014","journal-title":"BMJ"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"347","DOI":"10.7326\/M14-0178","article-title":"Fluid resuscitation in sepsis: a systematic review and network meta-analysis","volume":"161","author":"B Rochwerg","year":"2014","journal-title":"Ann Intern Med"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2307\/3001666","article-title":"The combination of estimates from different experiments","volume":"10","author":"WG Cochran","year":"1954","journal-title":"Biometrics"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"JP Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1503\/cmaj.081086","article-title":"Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses","volume":"181","author":"JP Ioannidis","year":"2009","journal-title":"CMAJ"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s00296-014-2994-2","article-title":"Network meta-analysis for comparing treatment effects of multiple interventions: an introduction","volume":"34","author":"F Catal\u00e1-L\u00f3pez","year":"2014","journal-title":"Rheumatol Int"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","article-title":"Conceptual and technical challenges in network meta-analysis","volume":"159","author":"A Cipriani","year":"2013","journal-title":"Ann Intern Med"},{"key":"ref69","first-page":"597","article-title":"The transitive property across randomized controlled trials: if B is better than A, and C is better than B, will C be better than A?","volume":"67","author":"F Catal\u00e1-L\u00f3pez","year":"2014","journal-title":"Rev Esp Cardiol"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0272989X12458724","article-title":"Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"S Dias","year":"2013","journal-title":"Med Decis Making"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1214\/ss\/1177011136","article-title":"Inference from iterative simulation using multiple sequences","volume":"7","author":"A Gelman","year":"1992","journal-title":"Stat Sci"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/0272989X12455847","article-title":"Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials","volume":"33","author":"S Dias","year":"2013","journal-title":"Med Decis Making"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"G Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1177\/0272989X13485157","article-title":"Evidence synthesis for decision making 3: heterogeneity\u2014subgroups, meta-regression, bias, and bias-adjustment","volume":"33","author":"S Dias","year":"2013","journal-title":"Med Decis Making"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"LF Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1136\/bmj.329.7477.1248","article-title":"Angiotensin receptor blockers and myocardial infarction","volume":"329","author":"S Verma","year":"2004","journal-title":"BMJ"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1161\/CIRCULATIONAHA.105.594986","article-title":"Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox","volume":"114","author":"MH Strauss","year":"2006","journal-title":"Circulation"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/hrt.2006.107185","article-title":"More about the \u201cARB MI paradox\u201d","volume":"93","author":"AS Hall","year":"2007","journal-title":"Heart"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"d2193","DOI":"10.1136\/bmj.d2193","article-title":"Angiotensin receptor blockers and cardiovascular outcomes","volume":"342","author":"FD Hobbs","year":"2011","journal-title":"BMJ"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s00125-011-2325-z","article-title":"Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study","volume":"54","author":"E Imai","year":"2011","journal-title":"Diabetologia"},{"key":"ref81","unstructured":"US Food and Drug Safety Administration. FDA drug safety communication: FDA review of cardiovascular risks for diabetics taking hypertension drug olmesartan not conclusive; label updates required. 2014 Jun 6 [cited 12 Jun 2015]. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm402323.htm\" xlink:type=\"simple\">http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm402323.htm<\/ext-link>."},{"key":"ref82","unstructured":"European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC). Minutes of the Meeting\u201429\u201331 October 2012. 2012 Nov 29 [cited 12 Jun 2015]. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Minutes\/2012\/12\/WC500135712.pdf\" xlink:type=\"simple\">http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Minutes\/2012\/12\/WC500135712.pdf<\/ext-link>."},{"key":"ref83","unstructured":"European Medicines Agency. European Medicines Agency recommends new contraindications and warnings for aliskiren-containing medicines. 2012 Feb 17 [cited 2 Jun 2015]. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2012\/02\/news_detail_001446.jsp&mid=WC0b01ac058004d5c1\" xlink:type=\"simple\">http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2012\/02\/news_detail_001446.jsp&amp;mid=WC0b01ac058004d5c1<\/ext-link>."},{"key":"ref84","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/eurjhf\/hfq212","article-title":"Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study","volume":"13","author":"H Krum","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1093\/eurheartj\/eht366","article-title":"Diabetes, aliskiren, and heart failure: let\u2019s bring ASTRONAUT down to earth","volume":"34","author":"JG Cleland","year":"2013","journal-title":"Eur Heart J"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1136\/bmj.330.7491.594","article-title":"Validity of composite end points in clinical trials","volume":"330","author":"VM Montori","year":"2005","journal-title":"BMJ"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1136\/bmj.39136.682083.AE","article-title":"Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials","volume":"334","author":"I Ferreira-Gonz\u00e1lez","year":"2007","journal-title":"BMJ"}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1002064","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,6,10]],"date-time":"2016-06-10T00:00:00Z","timestamp":1465516800000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pmed.1001971","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T21:38:13Z","timestamp":1588973893000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1001971"}},"subtitle":[],"editor":[{"given":"Maarten W.","family":"Taal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,3,8]]},"references-count":87,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,3,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1001971","relation":{"correction":[{"id-type":"doi","id":"10.1371\/journal.pmed.1002064","asserted-by":"object"}]},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,8]]}}}